HIV T cell vaccines, the importance of clades

Vaccine. 2002 May 6;20(15):1918-21. doi: 10.1016/s0264-410x(02)00067-1.

Abstract

Development of an HIV vaccine presents a formidable challenge. One of the unresolved, yet central issues is the importance of HIV variability. Here we argue that even with the recent focus on the induction of T cell-mediated immunity, HIV vaccines should match the local circulating HIV clades. Whether used alone or in a combination with vaccines eliciting HIV-neutralizing antibodies, efforts must be made to develop a T cell vaccine that stimulates a broad and long-lasting response.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines*
  • Amino Acid Sequence
  • Animals
  • Antigen Presentation
  • Antigenic Variation*
  • Clinical Trials, Phase I as Topic
  • Epitopes / immunology
  • HIV / classification*
  • HIV / genetics
  • HIV / immunology
  • HIV Antibodies / biosynthesis
  • HIV Antigens / chemistry
  • HIV Antigens / genetics
  • HIV Antigens / immunology*
  • HIV Infections / epidemiology
  • HIV Infections / virology
  • HLA Antigens / immunology
  • Humans
  • Immunity, Cellular
  • Immunologic Memory
  • Interleukin-2 / immunology
  • Kenya / epidemiology
  • Macaca
  • Mice
  • Neutralization Tests
  • Structure-Activity Relationship
  • T-Lymphocytes, Cytotoxic / immunology*
  • Vaccines, DNA
  • Vaccines, Synthetic

Substances

  • AIDS Vaccines
  • Epitopes
  • HIV Antibodies
  • HIV Antigens
  • HLA Antigens
  • Interleukin-2
  • Vaccines, DNA
  • Vaccines, Synthetic